FIGURE LEGENDS
Figure 1 Flow chart of survival analysis examining all-cause mortality in patients with pulmonary arterial hypertension (PAH) reported in the Japanese Adverse Drug Event Report database (JADER)
K-M, Kaplan-Meier; DOAC, direct oral anticoagulant
Figure 2 Comparison of the effects of pulmonary vasodilators on long-term survival in patients with pulmonary arterial hypertension reported in the Japanese Adverse Drug Event Report database
A, Kaplan-Meier curves of continuous infusion therapy with drugs targeting the prostacyclin pathway; B, Kaplan-Meier curves of inhalants and oral drugs targeting the prostacyclin pathway; C, Kaplan-Meier curves of drugs targeting the nitric oxide pathway; D, Kaplan-Meier curves of drugs targeting the endothelin pathway. P values were determined by the log-rank test.
Figure 3 The effects of supportive therapy on long-term survival in patients with pulmonary arterial hypertension reported in the Japanese Adverse Drug Event Report database
A, Kaplan-Meier curves of oxygen therapy; B, Kaplan-Meier curves of anticoagulant therapy with warfarin (Wf) with or without concomitant epoprostenol (Epo); C, Kaplan-Meier curves of anticoagulant therapy with direct oral anticoagulant (DOAC); D, Kaplan-Meier curves of diuretic therapy with tolvaptan. P values were determined by the log-rank test.